Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus HYDROCORTISONE AND ACETIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus HYDROCORTISONE AND ACETIC ACID.
ADVAIR DISKUS 500/50 vs HYDROCORTISONE AND ACETIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP, leading to bronchodilation. Fluticasone propionate is a corticosteroid with anti-inflammatory activity, inhibiting inflammatory cell infiltration and mediator release.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
ADVAIR DISKUS 500/50: One inhalation (fluticasone propionate 500 mcg and salmeterol 50 mcg) twice daily (approximately 12 hours apart).
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
None Documented
None Documented
Fluticasone propionate: terminal elimination half-life is approximately 7.8 hours. Salmeterol: terminal elimination half-life is approximately 5.5 hours. Clinically, the half-life supports twice-daily dosing for sustained bronchodilation and anti-inflammatory effects.
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
Fluticasone propionate: primarily hepatic (cytochrome P450 3A4) metabolism; renal excretion accounts for <5% as unchanged drug; fecal excretion accounts for the majority as metabolites. Salmeterol: primarily hepatic metabolism; renal excretion accounts for approximately 25% of the dose; fecal excretion accounts for approximately 60%.
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Category C
Category D/X
Corticosteroid/LABA Combination
Corticosteroid